世界のポックスウイルス感染症治療薬市場レポート2020年

QYResearchが発行した調査報告書(QYR21FB11476)
◆英語タイトル:Global Poxviridae Infections Drug Sales Market Report 2020
◆商品コード:QYR21FB11476
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年1月(※2024年版があります。お問い合わせください。)
◆ページ数:149
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品、医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD8,000 ⇒換算¥1,184,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

QYリサーチ社の本調査レポートでは、世界のポックスウイルス感染症治療薬市場について種類別(CJ-40011、24a、BA-368、その他)、用途別(病院、診療所、その他)、地域別(アメリカ、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2015年~2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。
・ポックスウイルス感染症治療薬市場の概要
・世界の主要地域別ポックスウイルス感染症治療薬市場規模2015-2026
・主要プレイヤーの競争状況・市場シェア
・世界のポックスウイルス感染症治療薬市場規模2015-2026:種類別(CJ-40011、24a、BA-368、その他)
・世界のポックスウイルス感染症治療薬市場規模2015-2026:用途別(病院、診療所、その他)
・ポックスウイルス感染症治療薬のアメリカ市場規模2015-2020
・ポックスウイルス感染症治療薬のヨーロッパ市場規模2015-2020
・ポックスウイルス感染症治療薬の中国市場規模2015-2020
・ポックスウイルス感染症治療薬の日本市場規模2015-2020
・ポックスウイルス感染症治療薬の東南アジア市場規模2015-2020
・ポックスウイルス感染症治療薬のインド市場規模2015-2020
・主要プレイヤーの企業情報:事業概要・売上・企業動向
・ポックスウイルス感染症治療薬の製造コスト分析
・販売チャネル、流通業者、顧客
・ポックスウイルス感染症治療薬の市場動向・機会・課題
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Poxviridae Infections Drug Market
The global Poxviridae Infections Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Global Poxviridae Infections Drug Scope and Market Size
The global Poxviridae Infections Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Poxviridae Infections Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Poxviridae Infections Drug market is segmented into
CJ-40011
24a
BA-368
Others

Segment by Application, the Poxviridae Infections Drug market is segmented into
Hospital
Clinic
Others

The Poxviridae Infections Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Poxviridae Infections Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Poxviridae Infections Drug Market Share Analysis
Poxviridae Infections Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Poxviridae Infections Drug business, the date to enter into the Poxviridae Infections Drug market, Poxviridae Infections Drug product introduction, recent developments, etc.

The major vendors covered:
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
China Biologic Products, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
N & N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.

【レポートの目次】

1 Poxviridae Infections Drug Market Overview
1.1 Poxviridae Infections Drug Product Scope
1.2 Poxviridae Infections Drug Segment by Type
1.2.1 Global Poxviridae Infections Drug Sales by Type (2020-2026)
1.2.2 CJ-40011
1.2.3 24a
1.2.4 BA-368
1.2.5 Others
1.3 Poxviridae Infections Drug Segment by Application
1.3.1 Global Poxviridae Infections Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Poxviridae Infections Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Poxviridae Infections Drug Sales Growth Rate (2015-2026)
1.4.2 Global Poxviridae Infections Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Poxviridae Infections Drug Price Trends (2015-2026)

2 Poxviridae Infections Drug Estimate and Forecast by Region
2.1 Global Poxviridae Infections Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Poxviridae Infections Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Poxviridae Infections Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Poxviridae Infections Drug Revenue Market Share by Region (2015-2020)
2.3 Global Poxviridae Infections Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Poxviridae Infections Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Poxviridae Infections Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.2 Europe Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.3 China Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.4 Japan Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.6 India Poxviridae Infections Drug Estimates and Projections (2015-2026)
3 Global Poxviridae Infections Drug Competition Landscape by Players
3.1 Global Top Poxviridae Infections Drug Players by Sales (2015-2020)
3.2 Global Top Poxviridae Infections Drug Players by Revenue (2015-2020)
3.3 Global Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Poxviridae Infections Drug as of 2019)
3.4 Global Poxviridae Infections Drug Average Price by Company (2015-2020)
3.5 Manufacturers Poxviridae Infections Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Poxviridae Infections Drug Players (Opinion Leaders)
4 Global Poxviridae Infections Drug Market Size by Type
4.1 Global Poxviridae Infections Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Poxviridae Infections Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Poxviridae Infections Drug Price by Type (2015-2020)
4.2 Global Poxviridae Infections Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Poxviridae Infections Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Poxviridae Infections Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Poxviridae Infections Drug Price Forecast by Type (2021-2026)
5 Global Poxviridae Infections Drug Market Size by Application
5.1 Global Poxviridae Infections Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Poxviridae Infections Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Poxviridae Infections Drug Price by Application (2015-2020)
5.2 Global Poxviridae Infections Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Poxviridae Infections Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Poxviridae Infections Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Poxviridae Infections Drug Price Forecast by Application (2021-2026)

6 United States Poxviridae Infections Drug Market Facts & Figures
6.1 United States Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
6.2 United States Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
6.3 United States Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

7 Europe Poxviridae Infections Drug Market Facts & Figures
7.1 Europe Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
7.2 Europe Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
7.3 Europe Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

8 China Poxviridae Infections Drug Market Facts & Figures
8.1 China Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
8.2 China Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
8.3 China Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

9 Japan Poxviridae Infections Drug Market Facts & Figures
9.1 Japan Poxviridae Infections Drug Sales Market Share by Company (3015-3030)
9.2 Japan Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
9.3 Japan Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

10 Southeast Asia Poxviridae Infections Drug Market Facts & Figures
10.1 Southeast Asia Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

11 India Poxviridae Infections Drug Market Facts & Figures
11.1 India Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
11.2 India Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
11.3 India Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Poxviridae Infections Drug Business
12.1 Bavarian Nordic A/S
12.1.1 Bavarian Nordic A/S Corporation Information
12.1.2 Bavarian Nordic A/S Business Overview
12.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Products Offered
12.1.5 Bavarian Nordic A/S Recent Development
12.2 BioFactura, Inc.
12.2.1 BioFactura, Inc. Corporation Information
12.2.2 BioFactura, Inc. Business Overview
12.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 BioFactura, Inc. Poxviridae Infections Drug Products Offered
12.2.5 BioFactura, Inc. Recent Development
12.3 CEL-SCI Corporation
12.3.1 CEL-SCI Corporation Corporation Information
12.3.2 CEL-SCI Corporation Business Overview
12.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 CEL-SCI Corporation Poxviridae Infections Drug Products Offered
12.3.5 CEL-SCI Corporation Recent Development
12.4 Chimerix, Inc.
12.4.1 Chimerix, Inc. Corporation Information
12.4.2 Chimerix, Inc. Business Overview
12.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Chimerix, Inc. Poxviridae Infections Drug Products Offered
12.4.5 Chimerix, Inc. Recent Development
12.5 China Biologic Products, Inc.
12.5.1 China Biologic Products, Inc. Corporation Information
12.5.2 China Biologic Products, Inc. Business Overview
12.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Products Offered
12.5.5 China Biologic Products, Inc. Recent Development
12.6 CJ HealthCare Corp.
12.6.1 CJ HealthCare Corp. Corporation Information
12.6.2 CJ HealthCare Corp. Business Overview
12.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Products Offered
12.6.5 CJ HealthCare Corp. Recent Development
12.7 EpiVax, Inc.
12.7.1 EpiVax, Inc. Corporation Information
12.7.2 EpiVax, Inc. Business Overview
12.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 EpiVax, Inc. Poxviridae Infections Drug Products Offered
12.7.5 EpiVax, Inc. Recent Development
12.8 N & N Pharmaceuticals Inc.
12.8.1 N & N Pharmaceuticals Inc. Corporation Information
12.8.2 N & N Pharmaceuticals Inc. Business Overview
12.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
12.8.5 N & N Pharmaceuticals Inc. Recent Development
12.9 SIGA Technologies, Inc.
12.9.1 SIGA Technologies, Inc. Corporation Information
12.9.2 SIGA Technologies, Inc. Business Overview
12.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Products Offered
12.9.5 SIGA Technologies, Inc. Recent Development
12.10 Takeda Pharmaceutical Company Limited
12.10.1 Takeda Pharmaceutical Company Limited Corporation Information
12.10.2 Takeda Pharmaceutical Company Limited Business Overview
12.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Products Offered
12.10.5 Takeda Pharmaceutical Company Limited Recent Development
12.11 Tonix Pharmaceuticals Holding Corp.
12.11.1 Tonix Pharmaceuticals Holding Corp. Corporation Information
12.11.2 Tonix Pharmaceuticals Holding Corp. Business Overview
12.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Products Offered
12.11.5 Tonix Pharmaceuticals Holding Corp. Recent Development
12.12 Verrica Pharmaceuticals Inc.
12.12.1 Verrica Pharmaceuticals Inc. Corporation Information
12.12.2 Verrica Pharmaceuticals Inc. Business Overview
12.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
12.12.5 Verrica Pharmaceuticals Inc. Recent Development

13 Poxviridae Infections Drug Manufacturing Cost Analysis
13.1 Poxviridae Infections Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Poxviridae Infections Drug
13.4 Poxviridae Infections Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Poxviridae Infections Drug Distributors List
14.3 Poxviridae Infections Drug Customers

15 Market Dynamics
15.1 Poxviridae Infections Drug Market Trends
15.2 Poxviridae Infections Drug Opportunities and Drivers
15.3 Poxviridae Infections Drug Market Challenges
15.4 Poxviridae Infections Drug Market Restraints
15.5 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

...

【掲載企業】

Bavarian Nordic A/S、BioFactura, Inc.、CEL-SCI Corporation、Chimerix, Inc.、China Biologic Products, Inc.、CJ HealthCare Corp.、EpiVax, Inc.、N & N Pharmaceuticals Inc.、SIGA Technologies, Inc.、Takeda Pharmaceutical Company Limited、Tonix Pharmaceuticals Holding Corp.、Verrica Pharmaceuticals Inc.

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のポックスウイルス感染症治療薬市場レポート2020年(Global Poxviridae Infections Drug Sales Market Report 2020)]についてメールでお問い合わせはこちらでお願いします。